Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Report Date: August 11, 2022
Reporting Period: Second Quarter ended June 30, 2022
This filing serves to announce the Company's financial results for the quarter ended June 30, 2022, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. The filing states that the full financial results, including revenue, profit, cash flow, margins, debt, and liquidity metrics, are detailed in the press release attached as Exhibit 99.1. Consequently, no specific financial values can be extracted from this document alone.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release containing management's discussion of the results.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that Section, nor is it incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K cover sheet.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2022 revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the incorporated exhibit.
- Confirm the status of any debt obligations or financing activities not detailed in this summary.